Opinion|Videos|November 18, 2024
Tailoring Patient Education and Resources in HER2+ Breast Cancer
Panelists discuss how education and resources are provided to patients with breast cancer upon diagnosis, highlighting the importance of tailoring educational approaches to individual needs and preferences, and they also explore the various courses, books, and resources that patients have found helpful in their self-education journey.
Advertisement
Episodes in this series
- Dr Iyengar asks Odessa Williams: What education or resources do you provide to patients with breast cancer upon diagnosis?
- Dr Iyengar: Briefly discuss how you tailor your approach to patient education based on their needs and preferences.
- Dr Iyengar asks Dorian Nygard: Which educational courses, books, and other resources allowed you to best educate yourself?
Advertisement
Related to this article
Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.
In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?
3
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
4
FDA OKs Pirtobrutinib in Frontline CLL/SLL
5